Annotation Detail
Information
- Associated Genes
- PDGFRA
- Associated Variants
- PDGFRA FIP1L1-PDGFRA
- Associated Disease
- acute myeloid leukemia
- Source Database
- CIViC Evidence
- Description
- In a preclinical trial, the AML cell line EOL1with the FIP1L1-PDGFRa fusion mutation was treated with the tyrosine kinase inhibitors (TKI) ponatinib, sorafenib, and sunitinib. Ponatinib was similarly effective in the growth inhibition of cells harboring the fusion mutation (IC50=0.5 nmol/L) compared to sorafenib (IC50=0.5 nmol/L) and sunitinib (IC50=3 nmol/L).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/7378
- Gene URL
- https://civic.genome.wustl.edu/links/genes/38
- Variant URL
- https://civic.genome.wustl.edu/links/variants/574
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Acute Myeloid Leukemia
- Evidence Direction
- Supports
- Drug
- Sunitinib,Sorafenib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 21482694